

QUANTITY LIMIT CRITERIA

DRUG CLASS [ANTIVIRAL FOR THE TREATMENT OF COVID-19]

BRAND NAME
(generic) (molnupiravir)

Status: CVS Caremark Criteria
Type: Quantity Limit

POLICY

USES

Emergency use authorization for the treatment of mild-to-moderate COVID-19 in adults with positive results of direct severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral testing, who are at high risk for progression to severe COVID-19, including hospitalization or death, and for whom alternative COVID-19 treatment options authorized by FDA are not accessible or clinically appropriate.

REFERENCES

1. Molnupiravir [Emergency Use Authorization Fact Sheet for Healthcare Providers]. Kenilworth, NJ: Merck & Co. Inc.; December 23, 2021.

LIMIT CRITERIA

<u>Drug</u>	<u>Limit*</u>
Molnupiravir 200 mg capsule	40 capsules / 30 days

*** This drug is for short-term acute use.**